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Ascaris suum is a widespread parasitic nematode that causes infection in pigs with high 22 
prevalence rates. Oxfendazole (OFZ) is effective against A. suum when used at a single 23 
high oral dose of 30 mg/kg. The aim of this study was to assess the pattern of 24 
distribution/accumulation of OFZ and its metabolites, in bloodstream (plasma), mucosal 25 
tissue and contents from small and large intestine and adult specimens of A. suum 26 
collected from infected and treated pigs. The activity of glutathione-S-transferases 27 
(GSTs) in A. suum was also investigated. Infected pigs were orally treated with OFZ (30 28 
mg/kg) and sacrificed at 0, 3, 6 and 12 h after treatment. Samples of blood, mucosa and 29 
contents from both small and large intestine as well as adult worms were obtained and 30 
processed for quantification of OFZ/metabolites by HPLC. OFZ was the main analyte 31 
measured in all of the evaluated matrixes. The highest drug concentrations were 32 
determined in small (AUC0-t 718.7 ± 283.5 µg.h/g) and large (399.6 ± 110.5 µg.h/g) 33 
intestinal content. Concentrations ranging from 1.35 to 2.60 µg/g (OFZ) were measured 34 
in adult A. suum. GSTs activity was higher after exposure to OFZ both in vivo and ex 35 
vivo. The data obtained here suggest that the pattern of OFZ accumulation in A. suum 36 
would be more related to the concentration achieved in the fluid and mucosa of the small 37 
intestine than in other tissues/fluids. It is expected that increments in the amount of drug 38 
attained in the tissues/fluids of parasite location will correlate with increased drug 39 
concentration within the target parasite, and therefore with the resultant treatment 40 
efficacy. The results are particularly relevant considering the potential of OFZ to be used 41 
for soil transmitted helminths (STH) control programs and the advantages of pigs as a 42 
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1.  Introduction  47 
The nematodes Ascaris lumbricoides and Ascaris suum are widespread parasites of 48 
humans and pigs, respectively. Human ascariosis is one of the most common soil 49 
transmitted helminths infections (STH), and is transmitted through soil contaminated with 50 
human faeces containing parasite eggs (WHO, 2018). Current estimations indicate that 51 
about a quarter (25%) of the world’s population currently has a STH infection (WHO, 52 
2018). Additionally, a high prevalence of gastrointestinal helminthic infections has been 53 
found in pig farms (Carstensen et al., 2002), and A. suum belongs to the list of the most 54 
important species found (Nansen and Roepstorff et al., 1999), causing a chronic illness 55 
that varies with geographical region and farm management practices (Dold and Holland, 56 
2010). Porcine ascariasis interferes with the health and performance of pigs, leading to 57 
economic losses (Stewart and Hale, 1988).  58 
The control of Ascaris spp. is largely based on the use of anthelmintic drugs. The 59 
benzimidazole and avermectin compounds are the most used chemical groups. 60 
Fortunately, Ascaris spp. is extremely susceptible to the aforementioned chemicals. The 61 
clinical efficacy of an anthelmintic will depend on its ability to reach high and sustained 62 
concentrations within the target parasite (pharmacokinetics), and to bind its specific 63 
receptor (pharmacodynamics) for sufficient time to induce the anthelmintic effect (Alvarez 64 
et al., 2007; Ceballos et al., 2009). The pharmacokinetics phase involves the time course 65 
of drug absorption, distribution, metabolism and elimination from the host, which, in turn, 66 
determines the concentration of the active drug reaching the site of parasite location. 67 













drug/metabolite to reach their specific receptor within the target parasite (Alvarez et al., 69 
2007). Thus, drug entry and the accumulation pattern in target helminths are critical 70 
issues to ensure optimal efficacy. The acquired knowledge supports a close relationship 71 
between the drug´s pharmacokinetic behaviour in the host and the observed final 72 
anthelmintic response (Alvarez et al., 2007).  73 
Benzimidazole (BZD) compounds are widely used in veterinary medicine as broad 74 
spectrum anthelmintics, showing a high efficacy against most nematode parasites 75 
(McKellar and Scott, 1990). Several of them, including fenbendazole (FBZ), have shown 76 
efficacy against A. suum after their administration at different doses in feed (Campbell, 77 
1990). Oxfendazole (OFZ) is the active sulphoxide metabolite of FBZ which was first 78 
marketed to be used in cattle, sheep and horses, for the removal and control of 79 
tapeworms (heads and segments), abomasal and intestinal nematodes (adults and 4th 80 
stage larvae) and lungworms (adults and larval stages) (Williams and Broussard, 1994). 81 
Fenbendazole have also ovicidal activity and is effective for the treatment of Giardia 82 
infection in calves (O’Handley et al., 1997). OFZ is recommended for the control of the 83 
same parasites as its sulfide parent compound (fenbendazole). Besides, its oral 84 
administration at a single dose of 30 mg/kg has been reported to be safe (Alvarez et al., 85 
2013) and highly effective for the treatment of cysticercosis (Gonzalez et al., 1996), 86 
fasciolosis (Ortiz et al., 2014) and adult stages of A. suum, Oesophagostomum spp., 87 
Trichuris suis and Metastrongylus spp. (Alvarez et al., 2013).  88 
Glutathione-S-transferases (GSTs) are a family of multifunctional enzymes essentially 89 
involved in the detoxification of harmful electrophilic endogenous and exogenous 90 
compounds by conjugation of glutathione with target molecules, and also function as 91 
non-enzymatic binding proteins involved in intracellular transport (Listowsky et al., 1988) 92 













fact, GSTs appears to be one of the major detoxification enzymes in parasitic helminths 94 
(Precious and Barrett, 1989), including A. suum (Liebau et al., 1994). The impact of OFZ 95 
on GSTs activity in A. suum recovered from treated pigs has not been investigated, but it 96 
could help to understand the drug effect on this important enzyme family.  97 
OFZ could be an alternative anthelmintic to be used in human medicine. Consequently, it 98 
is interesting to understand the pharmacological basis supporting its anthelmintic effect 99 
and the pattern of drug accumulation inside target parasites. A. suum infections in pigs 100 
are the very best experimental animal model available to understand the drug-target 101 
parasite relationship (Boes and Helwigh, 2000). Information describing the 102 
OFZ/metabolites plasma disposition kinetics and tissue residue profiles used at high 103 
doses (30 mg/kg), and its efficacy against gastrointestinal nematodes in pigs, is available 104 
(Moreno et al., 2012; Alvarez et al., 2013). However, the drug concentration profiles 105 
within the different fluid/tissues where target parasites are located; is unknown. To 106 
achieve further comprehension of the in vivo concentrations required to kill A. suum 107 
specimens in the pig’s gastrointestinal tract, the accumulation of OFZ and its metabolites 108 
in blood, mucosal tissue and luminal contents of the small and large intestine and in 109 
adults specimens of A. suum from OFZ treated pigs. As a complementary indicator of 110 
drug exposure to the worm, the in vivo and ex vivo OFZ effect on GSTs activity was 111 
investigated. 112 
  113 
2. MATERIALS AND METHODS  114 
2.1. Chemicals  115 
Pure reference standards (99% purity) of OFZ, FBZ and FBZSO2 were from Toronto 116 
Chemicals Research Inc. (Toronto, Canada). Oxibendazole (OBZ) and albendazole 117 













solvents acetonitrile and methanol were from Baker, Mallinckrodt (Baker, Phillipsburg, 119 
USA). Ethyl acetate was from Anedra (BA, Argentina). Water was distilled and deionized 120 
using a water purification system (Simplicity®, Millipore, São Paulo, Brazil). The OFZ 121 
administered to pigs was Synanthic® 9.06% (Merial, France).  122 
  2.2. Animals and experimental design       123 
The study was conducted in eight pigs (15 ± 2.7 kg, 2 months old, local ecotypes breed), 124 
naturally infected with A. suum. Pigs were fed ad libitum with a commercial balanced 125 
food and had free access to water. Parasite infection was confirmed by faecal egg counts 126 
(FEC) performed by the McMaster technique modified by Roberts and O’sullivan (1950). 127 
A 10 days acclimatization period was allowed for the experimental animals to adapt. 128 
Animals were housed in pens with concrete floors, protected from rain and prevailing 129 
winds, but without temperature control. Animal procedures and management protocols 130 
were carried out in accordance with the Animal Welfare Policy (Act 087/02) of the Faculty 131 
of Veterinary Medicine, Universidad Nacional del Centro de la Provincia de Buenos Aires 132 
(UNCPBA), Tandil, Argentina and internationally accepted animal welfare guidelines 133 
(AVMA, 2001).  134 
Schematic representation of the experimental design mentioned below is shown in Figure 135 
1. 136 
Drug tissue distribution trials: Experimental animals (n= 6) naturally infected with A. 137 
suum were orally treated with OFZ at the dose of 30 mg/kg. At 3, 6 and 12 h post-138 
treatment (p.t.), two (2) animals were sacrificed and samples of blood, A. suum, mucosal 139 
tissue and luminal contents of the GI tract were collected (small and large intestine) (Fig 140 
1). A. suum specimens were manually collected from pig’s intestine and rinsed 141 













immediately processed for drug/metabolites chemical extraction as detailed below. The 143 
total number of parasites recovered from each animal was registered. OFZ/metabolites 144 
concentration in A. suum was quantified only in worms recovered from the small 145 
intestine. Untreated animals (n= 2) were also sacrificed in order to obtain blank samples 146 
of blood, worms and gastrointestinal tissues/contents. After collection of the intestinal 147 
contents, the mucosal tissues of each gastrointestinal section were obtained by scraping. 148 
All obtained samples were placed into plastic tubes and frozen at -20 ºC until analysis by 149 
high performance liquid chromatography (HPLC).  150 
GSTs activity in vivo assay: The GSTs activity was assayed in A. suum specimens 151 
either from untreated or treated animals used in the Drug distribution assay (sacrificed at 152 
3 and 6 h p.t.) (Fig 1). The low number of worms recovered at 12 h p.t. precluded the 153 
assessment of GSTs activity at this sampling point. The parasites were rinsed 154 
extensively with saline solution (NaCl, 0.9%, 38 ºC) to remove adhering materials, blotted 155 
on coarse filter paper and placed in plastic tubes. From each animal, two samples of 4 A. 156 
suum specimens each were pooled and processed independently. The samples were 157 
kept in a freezer (−80°C). The procedure to obtain microsomal and cytosolic fractions 158 
from adult A. suum was adapted from the methodology described by Maté et al. (2008). 159 
Briefly, parasite samples were weighted and homogenized with two volumes of ice-cold 160 
homogenization buffer. Homogenates were filtered through and centrifuged at 10 000 x g 161 
for 20 min and the resulting supernatant at 100 000 x g for 65 min. Aliquots of 162 
supernatants (cytosolic fractions) were frozen in liquid nitrogen and stored at -70 ºC until 163 
used for GSTs activity assay. Pellets (microsomal preparations) were suspended in a 0.1 164 
M potassium phosphate buffer (containing 0.1 mM of EDTA and 20 % of glycerol), frozen 165 
in liquid nitrogen and stored at -70 ºC. An aliquot of cytosolic fraction was used to 166 













GSTs activity was assayed in the cytosolic fractions using 1-chloro, 2,4-dinitrobenzene 168 
(CDNB) as non specific substrate (Habig and Jakoby, 1981). The GSTs activity was 169 
determined by a continuous spectrophotometric method (Shimadzu Corporation, Kyoto, 170 
Japan).  171 
GSTs activity ex vivo assay: Specimens of A. suum were collected from the small 172 
intestine of untreated control pigs and processed as previously described for the GSTs in 173 
vivo assay. Worms were incubated for 1, 3 and 12 h at 37 ºC in 5 mL of the RPMI buffer 174 
containing OFZ at a final concentration of 5 µM (Fig 1). This is a pharmacologically 175 
relevant concentration. There were four replicate assays for each incubation time. Blank 176 
samples containing worms and incubation medium without drug were incubated over the 177 
same time intervals. Once the incubation time elapsed, worms were rinsed thoroughly 178 
with saline solution, blotted on coarse filter paper and processed as described in parasite 179 
assays in order to assess GST activity in cytosolic fractions. The parasite material was 180 
processed immediately after the incubation assays.  181 
The determination of parasite protein concentration was performed using the Lowry 182 
method with bovine serum albumin as standard (Lowry et al., 1951). GSTs activity is 183 
expressed as nmol/min/mg protein.  184 
2.3. Analytical procedures 185 
Plasma samples extraction: OFZ, FBZSO2 and FBZ were extracted from plasma by a 186 
method adapted from Lanusse et al., (1995). Briefly, plasma samples (1 mL) were spiked 187 
with OBZ used as IS and the molecules to be assayed (OFZ, FBZSO2, FBZ) in the 188 
validation procedure. Drug molecules were extracted by a solid phase extraction (SPE) 189 
procedure using C18 cartridges (Strata®, RP-18 100 mg, Phenomenex, CA, USA) 190 













HPLC water, dried with air for 5 min and eluted with 2 mL of methanol. The elution was 192 
evaporated to dryness under a gentle stream of nitrogen at 56 ºC in a water bath (Zymark 193 
TurboVap LV evaporator. American Laboratory Trading, Inc. Lyme 06333 CT, USA). The 194 
dry residue was dissolved in 250 µL of mobile phase (acetonitrile:water, 27:73). An aliquot 195 
(50 µL) of this solution was injected in the chromatographic system.  196 
A. suum and small/large intestinal mucosa samples extraction: Two whole parasites 197 
(female) from each animal (sampling at 3 and 6 h p.t.), were homogenized independently 198 
by means of scissors and scalpel, and 1g of each homogenate was used to quantify 199 
OFZ and its metabolites. In the case of the 12 h p.t. sampling time, in which only one 200 
parasite was obtained from each treated animal, two determinations were made for each 201 
one. As a result, four determinations for each time were obtained. In order to quantify 202 
OFZ/metabolites, samples (1 g) of parasite material and mucosa of the small and large 203 
intestines were homogenized and spiked with ABZSO as IS. Analytes were extracted by 204 
the addition of 1.5 mL of ethyl acetate. After shaking (50 min), the samples were 205 
sonicated for 10 min and centrifuged at 3800 rpm for 15 min at 4 ºC, and the clear 206 
supernatant (ethyl acetate phase) was transferred to a 5 mL glass tube. This procedure 207 
was repeated twice. The total supernatant (4.5 mL approx.) was evaporated to dryness 208 
under a gentle stream of nitrogen at 56 ºC in a water bath. For cleaning, the dry residue 209 
was dissolved in 2 mL of hexane and 1.5 mL of ACN and vigorously shaken (40 min). 210 
The hexane phase was then discarded. The samples were evaporated to dryness under 211 
a gentle stream of nitrogen at 56 ºC in a water bath.The dry extracts were reconstituted 212 
in 250 µL of mobile phase (acetonitrile:water, 27:73) and an aliquot of 50 µL was injected 213 
into the HPLC system. 214 
Small/large intestine luminal contents samples extraction: Samples of small and 215 













min. Analytes were extracted by the addition of 1.5 mL of ACN. After shaking (30 min), 217 
the samples were sonicated for 10 min and centrifuged at 3800 rpm (15 min, 4 ºC); the 218 
supernatant was transferred to a 5 mL glass tube. This procedure was repeated three 219 
times. The total supernatant (4.5 mL approx.) was evaporated to dryness under a gentle 220 
stream of dry nitrogen at 56 ºC in a water bath. The dry extracts were reconstituted in 221 
250 µL of mobile phase and an aliquot of 50 µL was injected into the HPLC system. 222 
Fluid phase of small intestine luminal content samples extraction: The fluid phase 223 
was separated from the particulate phase of small intestine luminal content by 224 
centrifugation at 3800 rpm (15 min, 4 ºC). Samples of fluid phase (0.5 mL) were spiked 225 
with ABZSO as IS.  Analytes were extracted by the addition of 1.5 mL of ACN. After 226 
shaking (15 min), and centrifugation (3800 rpm, 15 min, 4 ºC), the supernatant was 227 
separated and 1.5 mL of HPLC water were added. Subsequently, the samples were 228 
subjected to a solid phase extraction (SPE) identical to that mentioned above for the 229 
extraction of plasma samples. The dry extracts were reconstituted in 250 µL of mobile 230 
phase (acetonitrile:water, 27:73) and an aliquot of 50 µL was injected into the HPLC 231 
system. 232 
2.4. Drug quantification by HPLC: analysis and validation 233 
Experimental and fortified samples of each matrix (plasma, A. suum, mucosa and content 234 
of small and large intestine, and fluid phase of small intestinal content) were analysed by 235 
HPLC to determine the concentration of OFZ, FBZSO2 and FBZ. The HPLC system and 236 
method to quantify these compounds were as described by Moreno et al. (2012). 237 
Calibration curves for OFZ, FBZSO2 and FBZ in each matrix were prepared by least 238 
squares linear regression analysis, which showed correlation coefficients >0.994. Mean 239 













estimated in the concentration range of 0.1-5 µg/mL (plasma, parasite material and fluid 241 
phase of small intestinal content), 0.2-40 µg/mL (mucosa of small and large intestine), 242 
and 1-300 µg/mL (total content of small and large intestine), ranged between 72 and 95 243 
% with coefficients of variation (CV) ≤ 15 %. The limit of quantification (LOQ) was defined 244 
as the lowest measured concentration with a CV < 20%, an accuracy of ± 20% and an 245 
absolute recovery >70%. The limit of quantification was established at 0.1 µg/mL-g for 246 
plasma, parasite material and fluid phase of small intestinal content; 0.2 µg/g for mucosa 247 
of small and large intestine, and 1 µg/g for total content of small and large intestine. The 248 
limit of detection (LOD) was estimated by integrating the baseline threshold at the 249 
retention time of each compound for six non-spiked matrix samples. The LOD was 250 
defined as the mean 'noise'/internal standard peak area ratio plus 3 standard deviations 251 
(SD).  252 
2.5. Analysis of the data 253 
Data are expressed as arithmetic mean ± standard deviations (SD). The area under the 254 
concentration-time curve (AUC0-t) for OFZ, FBZSO2 and FBZ in each assayed tissue/fluid 255 
was calculated by the trapezoidal rule (Gibaldi and Perrier, 1982), using the 256 
PKSolutions™ computer program (Summit Research Service, Ashland, USA).  The 257 
AUC0-t value was considered to be an indicator of the total drug availability in each 258 
biological matrix assayed. Non-parametric (Mann-Whitney) tests were used for statistical 259 
comparison of GSTs activity in A. suum recovered from in vivo and ex vivo experiments.  260 
Correlation between individual concentrations of OFZ in A. suum/small intestinal content, 261 
A. suum/small intestinal fluid, A. suum/small intestinal mucosa and small intestinal 262 
content/small intestinal fluid was performed by parametric analysis (Pearson r, r2). A 263 
value of P<0.05 was considered statistically significant. Statistical analysis was 264 













3. RESULTS  266 
The presence of eggs in feces before starting the assay demonstrated that all animals 267 
involved were parasitized with A. suum. Adult A. suum were recovered from all sacrificed 268 
pigs.  A mean of 83 worms were recovered from untreated pigs, 87 from animals 269 
sacrificed at 3 h p.t. (4 of them were recovered from the large intestine), 44 from animals 270 
sacrificed at 6 h p.t. (13 of them were recovered from the large intestine), and only two 271 
(all located in the small intestine) at 12 h p.t..  272 
OFZ/metabolites concentrations (mean ± SD) measured in plasma, A. suum, mucosal 273 
tissue and contents of the small and large intestine after OFZ administration to pigs (30 274 
mg/kg) are presented in Table 1.  OFZ was the analyte quantified at highest 275 
concentrations in all tissues assayed and at all sampling times, representing about 91% 276 
of total analytes (OFZ, FBZSO2 and FBZ). This analyte reached high plasma levels (1.10 277 
± 0.1 µg/mL) at the first sampling time (3 h p.t. ) and achieved its plasma peak 278 
concentration (3.70 ± 1.30 µg/mL) within 6 h p.t., while in A. suum the maximum OFZ 279 
accumulation was observed at 12 h p.t. (2.60 ± 1.60 µg/g). In content of small intestine as 280 
well as in content and mucosa of large intestine, the highest OFZ concentrations were 281 
measured at the first sampling time (3 h p.t.).  282 
Figure 2 shows the comparative drug availability (expressed as AUC0-t) in each 283 
biological matrix, for OFZ, FBZSO2 and FBZ. The highest AUC0-t values for OFZ were 284 
observed in the small (718.7 ± 283.5 µg.h/g) and large (399.6 ± 110.5 µg.h/g) intestinal 285 
content followed by the large intestinal mucosa (131 ± 25.4 µg.h/g).  286 
Figure 3 shows the comparative concentrations and availability (AUC0-t) observed at 3, 6 287 
and 12 h p.t. in both the content and the fluid phase of the small intestine. OFZ 288 













content (3.3, 7.6 and 12.3% at 3, 6 and 12 h p.t., respectively). Accordingly, the 290 
proportion of OFZ not adsorbed to the particulate material of the small intestinal content 291 
which is dissolved in the fluid phase was roughly 4 %. Equivalent OFZ concentrations 292 
(ranging between 4.10 and 4.70 µg/g) were observed in samples of small intestinal 293 
mucosa of treated pigs at 3, 6 and 12 h p.t..    294 
FBZ metabolite was recovered mainly from samples of A. suum, mucosa of small and 295 
large intestinae and large intestinal content, at all sampling times (Table 1). Its 296 
concentrations in plasma, small intestinal content and fluid were below the limit of 297 
quantification (LOQ), which preclude any pharmacokinetic analysis (e.g. AUC 298 
estimation). Alike, concentrations below LOQ were measured for the inactive FBZSO2 299 
metabolite in the most tissues. This analyte could be quantified in samples of small 300 
intestinal mucosa and in some sampling times of plasma, A. suum and large intestinal 301 
content (Table 1). 302 
GSTs activities in A. suum specimens recovered from both untreated control and OFZ-303 
treated pigs (GSTs activity in vivo assay) and in worms incubated at different times 304 
with OFZ (GSTs activity ex vivo assay) are shown in Table 2. In the in vivo experiment, 305 
a higher (P< 0.05) GSTs activity was observed in A. suum recovered from OFZ- treated 306 
pigs at 3 h p.t. (183.0 ± 56.7 nmol/min/mg protein) than that obtained in worms from 307 
untreated controls (94.3 ± 31.6 nmol/min/mg protein). However, no statistical difference 308 
was observed between A. suum from untreated and 6 h treated pigs (103.3 ± 15.7 309 
nmol/min/mg protein). In the ex vivo experiment, OFZ induced an increment in GSTs 310 
activity in A. suum after 3 and 6 h of incubation (Table 2).   311 













Following the oral treatment of pigs with OFZ, a fast expulsion of the total nematode 313 
burden was observed. A. suum expulsion started as early as 3 h p.t., recovering worms 314 
from the distal section of the large intestine of treated pigs, and A. suum elimination was 315 
almost complete at 12 h p.t..  316 
OFZ was largely the main analyte quantified in all assayed samples. The high OFZ 317 
concentrations achieved after a single oral dose of 30 mg/kg in pigs may account for 318 
parasites being exposed to toxic drug concentrations for sufficient time, explaining the 319 
early elimination of A. suum observed in the current experiment. A fast increment in 320 
GSTs activity (3 h p.t.) was observed in worms exposed to OFZ (in vivo and ex vivo 321 
assays), compared to those observed in untreated control worms (Table 2). The 322 
increased GSTs activity in A. suum could indicate some kind of “response” of the 323 
nematode to protect himself from other biochemical alterations (e.g. oxidative stress) 324 
induced by  "toxic" concentrations of a xenobiotic such as OFZ. 325 
The present study was not performed to estimate worm kinetic expulsion after OFZ 326 
treatment, but it is clear that A. suum is rapidly affected by high levels of the active 327 
compounds measured in the medium surrounding it (small intestinal content/fluid and 328 
mucosa), losing its capacity to remain in its specific site of location. The plasma profiles 329 
of OFZ/metabolites observed (Table 1) are in agreement with results reported by Moreno 330 
et al. (2012) since, after its oral administration, OFZ quickly reaches high plasma levels 331 
with a Tmax value as early as 6 h p.t.. The systemic exposure of BZD compounds 332 
reflects the amount of drug dissolved at the gastrointestinal level (Alvarez et al., 2013) 333 
which would be available for absorption and/or for diffusion through the external surface 334 
of parasites located at the gastrointestinal lumen; thus, the higher the drug present at 335 













The knowledge of drug concentrations achieved within target parasites and the 337 
tissues/fluids surrounding them, will contribute to the understanding of the 338 
pharmacokinetics-efficacy relationship. OFZ was de most representative analyte 339 
measured within the parasites (90 % of total drug). A. suum is located in the small 340 
intestine, swimming against the flow to maintain its specific location and feeding on with 341 
food digested by the host, in contact with the mucosa and surrounded by the intestinal 342 
content (Nansen and Roepstorff, 1999). Consequently, anthelmintic drugs can reach their 343 
target receptor in A. suum by transcuticular diffusion from the intestinal fluid and/or 344 
mucosa, and by intestinal absorption from the intestinal content ingested by the worm.  345 
After their administration, BZD compounds are rapidly adsorbed to the digesta particulate 346 
material, reaching an equilibrium between drug concentrations in particulate 347 
and fluid portions of content (Hennessy, 1993). In fact, we observed a highly positive 348 
correlation (r= 0.97) between OFZ concentrations in small intestinal content and in the 349 
small intestinal fluid. The amount of OFZ quantified in samples of small intestinal fluid 350 
reflects the dissolved drug portion able to diffuse through the external surface of A. suum; 351 
it represented only 3.45% (3 h p.t.), 12.2% (6 h p.t.) and 15.7% (12 h p.t.) of that 352 
observed in small intestinal content samples (ranging between 10.0 and 257 µg/mL) 353 
(Table 1). No correlation was observed (P> 0.05) between OFZ concentration in A. suum 354 
and fluid, content or mucosa of the small intestine; partly explained by the high variability 355 
observed in drug concentrations among the different samples. In addition, the OFZ 356 
concentration measured in either mucosa or content of the small intestine could partially 357 
contribute to the amounts of drug found in the parasite. This metabolite could reach the 358 
small intestinal mucosa from the peripheral blood after absorption through the 359 
gastrointestinal tract as well as through passive diffusion processes from it, in favour of 360 













Hansen et al. (2017) have reported that after treatment of pigs with OFZ (5 mg/kg), OFZ 362 
concentrations in the content and the mucosa of the large intestine were far higher than 363 
in plasma and inside the parasite Trichuris suis (other recognized nematode situated in 364 
GI tract with the anterior oesophageal part of the worm is embedded in the mucosa, while 365 
the posterior thick part is protruding freely into the lumen). They concluded that OFZ 366 
reaches T. suis after its gastrointestinal absorption by the host and posterior distribution 367 
to the parasites by a systemic circulation-enterocyte pathway. This statement was 368 
supported by a high correlation between drug concentrations of OFZ measured in host 369 
plasma and worms (Hansen et al., 2017). Besides, FBZ accumulated in the worms 370 
originates from the intestinal digesta of the host and some minor part would enter from 371 
the systemic circulation (Hansen et al., 2017). A similar T. suis drug-accumulation 372 
pathway was suggested for OFZ after the oral administration of FBZ to pigs (Hansen et 373 
al., 2014). In keeping with these authors’ observations, high OFZ concentrations either in 374 
mucosa or content of the large intestine were quantified in this study (Table 1). The use 375 
of a 30 mg/kg dose of OFZ exposed parasites located at the large intestine such as 376 
Oesophagostomum spp and Trichuris suis (normally “refractory” to anthelmintic 377 
treatments) to OFZ concentrations high enough to affect and eliminate them (Alvarez et 378 
al., 2013).  379 
Although low FBZ concentrations (range 0.13-0.29 µg/g) were measured in A. suum, its 380 
contribution to the anthelmintic effect should be taken into account. The greater 381 
anthelmintic activity of FBZ compared to OFZ has been demonstrated in vitro by 382 
assessing binding to parasite tubulin (Lacey and Gill, 1994) and nematode motility 383 
(Petersen et al., 1997). The higher anthelmintic potency of FBZ may partially compensate 384 
for its lower concentrations achieved inside the parasite, contributing to the final 385 













OFZ reduction to FBZ, mediated by the microbial activity taking place mainly in the pig´s 387 
large intestine (Moreno et al., 2012). In agreement with that, the highest FBZ 388 
concentrations were observed in samples of large intestinal content. Reduction by the 389 
gastrointestinal microflora plays an important role in the metabolism of a number of 390 
drugs, particularly those containing nitro and sulphoxide groups (Lanusse and Prichard, 391 
1993). FBZ may accumulate inside A. suum by diffusion through the external parasite 392 
surface from the surrounding medium. Since FBZ has a higher “diffusion rate” compared 393 
to OFZ due to its higher lipid solubility (Mottier et al., 2003), this metabolite accumulation 394 
into the worm could be occurring by passive diffusion from the low (below the limit of 395 
detection (0.1 µg/mL) concentrations of the drug present in the small intestinal fluid. 396 
Furthermore, FBZ concentrations quantified in small intestinal mucosa would also help to 397 
explain FBZ concentrations observed in worms. FBZSO2 metabolite was quantified in A. 398 
suum only at 12 h post-treatment, likely with a similar accumulation pattern to that 399 
described for FBZ. As we mentioned, the greater FBZ accumulation into A. suum 400 
compared to FBZSO2 could also be explained by differences in drug lipophilicity as a 401 
major determinant of the rate of transfer across the nematode cuticle (Thompson et al., 402 
1993, Mottier et al., 2003).  403 
5. Conclusions 404 
The drug concentrations reached in the small intestinal content of pigs, mostly the portion 405 
that is dissolved in the fluid phase of it, correlate with the drugs concentration 406 
accumulated in A. suum, which could have an impact in its pharmacology activity. It is 407 
clear that OFZ concentrations around 1-2 µg/g inside the worms are enough to eliminate 408 
adult A. suum. The characterization of the disposition kinetics of OFZ and its metabolites 409 













further contribution to the knowledge of the pharmacology of antiparasitic drugs aimed at 411 
optimizing parasite control. 412 
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Legends 493 
Figure 1: Schematic representation of the performed experimental design. Drug tissue 494 













GI tract are taken (small and large intestine) from pigs naturally infected with Ascaris 496 
suum and either untretated or orally treated with oxfendazole (OFZ) (30 mg/kg), and 497 
OFZ/metabolites are analyzed by HPLC. GST in vivo and ex vivo assay: GST activity is 498 
assayed in parasites recovered from animals used in either In vivo drug accumulation 499 
assay, sacrificed 3 and 6 h post OFZ treatment, or in parasites recovered from untreated 500 
control animals, incubated for 1, 6 and 12 h with OFZ (5 nm/mL).  501 
 502 
Figure 2: Comparative tissues availabilities of oxfendazole (OFZ), fenbendazole 503 
sulphone (FBZSO2) and fenbendazole (FBZ). Area under de concentration vs time curve 504 
(AUC0-t , µg.h/mL-g ) measured in plasma, A. suum, small intestinal mucosa , small 505 
intestinal content, small intestinal fluid, large intestinal mucosa and large intestinal 506 
content, from naturally infected pigs treated with oxfendazole (30 mg/kg). 507 
 508 
Figure 3: Comparative oxfendazole (OFZ) concentrations (arithmetic mean ± SD) 509 
detected in small intestinal content and fluid phase of small intestinal content (at 3, 6 and 510 
12 h after OFZ treatment (30 mg/kg) to naturally infected pigs.  The insert shows the 511 
comparative oxfendazole area under the concentration – time curve from 0 to 12 h 512 
(AUC0-t, µg.h/mL-g) measured in small intestinal content and small intestinal fluid 513 













Table 1:  
Concentrations (arithmetic mean ± SD) obtained for oxfendazole (OFZ), fenbendazole 
sulphone (FBZSO2) and fenbendazole (FBZ) in pigs orally treated with oxfendazole (30mg/kg), 
at 3, 6, and 12 h post treatment (p.t), in small intestinal mucosa, small intestinal content, small 
intestinal fluid phase, large intestinal mucosa and large intestinal luminal content.    
Time 
post-treatment (h) 
Tissue concentration (µg/mL -g) 














3  1.10 ± 0.10 1.80 ± 0.40 4.40 ± 1.40 171 ± 63.7 22.8 ± 0.30 70.5 ± 9.80 
6 3.70 ± 1.30 1.60 ± 0.40 4.10 ± 2.70 31.7 ± 19.1 8.40 ± 6.10 26.8 ± 17.6 
12 3.40 ± 0.70 2.60 ± 1.60 4.70 ± 3.10 21.1 ± 10.1 4.50 ± 1.20 24.5 ± 6.40 
FBZSO2 
3  <LOQ <LOQ 0.20 ± 0.10 n.d. <LOQ 1.30 ± 0.10 
6  0.20 ± 0.10 <LOQ 0.40 ± 0.10 n.d. <LOQ <LOQ 
12  0.40 ± 0.10 0.19 ± 0.19 0.60 ± 0.40 n.d. <LOQ <LOQ 
FBZ 
3 <LOQ 0.10 ± 0.10 0.30 ± 0.10 n.d <LOQ 3.30 ± 2.90 
6  <LOQ 0.20 ± 0.10 0.30 ± 0.10 n.d. 3.60 ± 1.50 5.50 ± 2.90 
12 <LOQ 0.20 ± 0.10 0.70 ± 0.30 n.d. 3.40 ± 0.90 5.10 ± 2.70 















Table 2:  
Glutathione S-transferase (GSTS) activity (nmol/min/mg protein) measured in adult 
Ascaris suum obtained at different times from pigs treated with oxfendazole (OFZ, 
30 mg/kg) (GSTS activity in vivo assay) and in A. suum ex vivo incubated with OFZ 
(5 nmoles/mL) for 1, 3 and 6 h (GSTS activity in vivo assay). 
Time post -treatment  In vivo assay GST activity  
0 h 94.3 ± 31.6 
3 h 183.0 ± 56.7* 
6 h 103.3 ± 15.7 
 
Incubation time 
Ex vivo assay b  GST activity  
Control  Exposed to OFZ 
0 h 99.5 ± 13.2 - 
1 h 123.5 ± 11.0 201.5 ± 73.5 
3h 121.0 ± 14.1 209.5 ± 17.1* 
6 h 121.5 ± 11.7 214.0 ± 33.6* 
Values represent means ± SD of four (4) replicate assays for each time. 















At 3, 6 and 12 h post treatment 
Sacrifice  
and sampling 
A. suum A. suum 
Untreated  
Control 
GST activity in vivo assay 
GST activity ex vivo assay 
A. suum 
3 h pt. 
6 h pt. 











Naturally infected pig 
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- Oxfendazole (OFZ) is effective against A. suum when used at a single high 
oral dose of 30 mg/kg. 
- The pattern of distribution/accumulation of OFZ and its metabolites, in adults 
A. suum and related tissues was investigated. 
- OFZ was the main analyte measured in all of the evaluated matrixes 
- The highest drug concentrations were determined in small and large  
intestinal content. 
- Concentrations ranging from 1.35 to 2.60 µg/g (OFZ) were measured in 
adult A. suum. 
- Increments in the amount of drug attained in the tissues/fluids of parasite 
location correlate with the resultant treatment efficacy. 
